Aktis Oncology (NASDAQ:AKTS – Get Free Report) and Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Earnings & Valuation
This table compares Aktis Oncology and Allogene Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aktis Oncology | $6.50 million | 137.43 | -$63.73 million | ($0.82) | -20.27 |
| Allogene Therapeutics | $20,000.00 | 14,529.22 | -$190.89 million | ($0.63) | -1.33 |
Profitability
This table compares Aktis Oncology and Allogene Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aktis Oncology | N/A | N/A | N/A |
| Allogene Therapeutics | N/A | -49.84% | -37.25% |
Insider and Institutional Ownership
28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of current recommendations for Aktis Oncology and Allogene Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aktis Oncology | 1 | 0 | 9 | 1 | 2.91 |
| Allogene Therapeutics | 1 | 3 | 8 | 2 | 2.79 |
Aktis Oncology currently has a consensus target price of $35.62, suggesting a potential upside of 114.35%. Allogene Therapeutics has a consensus target price of $8.30, suggesting a potential upside of 889.63%. Given Allogene Therapeutics’ higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Aktis Oncology.
Summary
Allogene Therapeutics beats Aktis Oncology on 7 of the 13 factors compared between the two stocks.
About Aktis Oncology
Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.
About Allogene Therapeutics
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for cancer. Its approach uses T cells from healthy donors to create potential off-the-shelf CAR T treatments, which are designed to be available without collecting and modifying each patient’s own cells. The company’s investigational programs include cema-cel, a CAR T candidate being studied for B-cell non-Hodgkin lymphomas, and ALLO-316, a candidate targeting CD70 that is being evaluated for kidney cancer.
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
